Cargando…

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20

Loss of CD20 is a major obstacle for the retreatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL) with Rituximab-associated regimens. Histone deacetylation causes gene silencing and inhibits CD20 expression. Chidamide is a novel inhibitor for histone deacetylases (HDACs). We hypothes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Xu-Wen, Wang, Hua-Qing, Ban, Wei-Wei, Chang, Zhi, Chen, Hai-Zhu, Jia, Li, Liu, Feng-Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944697/ https://www.ncbi.nlm.nih.gov/pubmed/31907371 http://dx.doi.org/10.1038/s41419-019-2210-0

Ejemplares similares

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
por: Kang, Junnan, et al.
Publicado: (2021)

Upregulation of CD22 by Chidamide promotes CAR T cells functionality
por: Yang, Xin, et al.
Publicado: (2021)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
por: Que, Yi, et al.
Publicado: (2021)

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report
por: Yang, Dan, et al.
Publicado: (2018)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
por: Wada, Naoki, et al.
Publicado: (2009)

Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation
por: Li, Yongpan, et al.
Publicado: (2022)

Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
por: Wang, Xing-Tong, et al.
Publicado: (2020)

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review
por: Chen, Chao, et al.
Publicado: (2021)

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma
por: Wang, Xing, et al.
Publicado: (2021)

Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report
por: He, Zhen-Dong, et al.
Publicado: (2022)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Cd20 Expression and Effects on Outcome of Relapsed/Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab
por: Rasheed, Afshan Asghar, et al.
Publicado: (2018)

Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma
por: Tian, Chen, et al.
Publicado: (2020)

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl-2 pathway
por: Zhang, Hongwei, et al.
Publicado: (2021)

The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations
por: Mishima, Y, et al.
Publicado: (2011)

Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells
por: Luo, Chengke, et al.
Publicado: (2016)

Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
por: Hao, Yuan-Yuan, et al.
Publicado: (2022)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
por: Song, Lina, et al.
Publicado: (2019)

Systemic anti-CD20 (rituximab) as primary treatment for symptomatic primary uveal lymphoma
por: Tiu Teo, Honeylen Maryl, et al.
Publicado: (2019)

Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study
por: Chen, Xinrui, et al.
Publicado: (2021)

Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma
por: Wen, Tingyu, et al.
Publicado: (2022)

Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review
por: Xu, Qing-Yuan, et al.
Publicado: (2022)

A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab
por: Chu, Te-Wei, et al.
Publicado: (2015)

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study
por: Petrini, Mario, et al.
Publicado: (2022)

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo
por: Damm, Jesper Kofoed, et al.
Publicado: (2015)

Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia
por: Gu, Siyu, et al.
Publicado: (2023)

Two Cases of Cerebral Involvement in Malignant Lymphoma (CD20+) That Responded to Combination Therapy with Rituximab and Cladribine
por: Jo, Tatsuro, et al.
Publicado: (2012)

5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report
por: Tsutsumi, Yutaka, et al.
Publicado: (2016)

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma
por: Wang, Jinni, et al.
Publicado: (2022)

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
por: Ridwansyah, Hastono, et al.
Publicado: (2023)

DIPG-26. Targeted Protein Degradation of LSD1 synergizes with HDAC inhibitors in Diffuse Intrinsic Pontine Glioma
por: Groves, Andrew, et al.
Publicado: (2022)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases
por: Peterlin, Pierre, et al.
Publicado: (2018)

Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster
por: Li, Huafei, et al.
Publicado: (2015)

CD20(+) cutaneous T-cell lymphoma with phenotypic shift after treatment with rituximab: Case report and review of the literature
por: Tschetter, Amanda J., et al.
Publicado: (2020)

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity
por: Tokunaga, Takashi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dkst69s1n51tegjftppf0onpgi